The present disclosure describes methods of treating infectious diseases with solid dosage forms comprising amphotericin B. In some embodiments, the disclosure provides methods of treating fungal infections and Lesishmania infection.

The present invention relates to a formulation sized for injection comprising a biodegradable polyesteramide co-polymer comprising at least a diol of bicyclic-1,4:3,6-dianhydrohexitol and analgesics for use in the treatment of arthritic disorders. More specific the invention relates to a formulation comprising injectable microparticle according to claim 1 wherein the polyesteramide co-polymer further comprises a diacid, a diol different from bicyclic-1,4:3,6-dianhydrohexitol and at least two different amino-acids. The formulation is used to treat pain or inflammation in a patient comprising administering to said patient a therapeutically effective amount of the formulation once or twice a year.

Water-soluble formulations including cannabinoids or a cannabis-derived compound for use in beverages and foods, methods of preparing the formulations, and methods of preparing beverages and foods including the formulations are disclosed herein. In other embodiments are provided water-soluble formulations that are physically and chemically stable, transparent or translucent in colour, calorie-free, and have minimal flavour.

The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.

The present invention provides microparticles comprising a sulphur-containing compound, such as cysteamine, or a pharmaceutically acceptable salt, hydrate or ester thereof. Also provided is a composition comprising the microparticles and a stabilizing agent.

The present disclosure concerns effervescent compositions and methods of making and using the same. In some embodiments, the disclosed effervescent compositions are formed from an input blend comprising an acid and a base by granulating the input blend in a twin-screw processor. The granules formed from the input blend can be formed by an in situ granulating agent, which can be a portion of the acid that melts during granulation. In some embodiments, the effervescent compositions can be made using a twin-screw processor comprising an intake zone for receiving an input blend comprising an acid and a base; a granulation initiation zone for melting only a portion of the acid to serve as an in situ granulating agent; a granulation completion zone for granulating the input blend; and an outlet for discharging the granules.

A granular product based on arginine or the derivatives thereof, comprises an internal core in which there is substantially concentrated the arginine and a coating for covering and protecting the internal core, wherein the coating is formed by a lipidic matrix comprising a fraction by weight equal to or greater than 60% of glycerides of saturated fatty acids C16 and C18 and a fraction by weight of a mineral salt of alginate between 0.5% and 3%.

Nanoparticle are described comprising a tannic acid, a trivalent metal ion, and a pharmaceutical agent comprising a water-soluble biologically active agent, such as a protein, a water-soluble peptide, small molecule or a combination thereof and methods of making and using the nanoparticles. Some nanoparticles of the present invention include 30-60% (w/w) of a tannic acid, 0.1-20% (w/w) of a trivalent metal ion, and 1-50% (w/w) of a pharmaceutical agent.

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.